Literature DB >> 11683924

Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy.

K Bodger1, J I Wyatt, R V Heatley.   

Abstract

BACKGROUND: It has long been recognised that specific patterns of gastritis are linked with different gastroduodenal diseases and that serum pepsinogens vary with the histological state of the gastric mucosa. With the discovery of the role of Helicobacter pylori in chronic gastritis and the availability of noninvasive tests for H. pylori infection, individuals with H. pylori gastritis can now be identified without endoscopic biopsy. However, without a knowledge of the pattern and severity of gastritis it is impossible to predict the likelihood of significant associated gastroduodenal pathology. AIMS: The aim of this study was to evaluate the diagnostic potential of serum pepsinogens I and II in predicting the topography and severity of gastritis in H. pylori-infected dyspeptic patients attending for endoscopy.
METHODS: Fasting serum was obtained from consecutive dyspeptic patients attending for endoscopy, and pairs of gastric biopsies obtained from the mid-body and antrum. Gastritis was graded according to the Sydney System, and serum pepsinogen levels determined by radio-immunoassay.
RESULTS: Sixty-nine dyspeptic patients were studied (mean age: 49.6 years) of whom 34 had H. pylori-associated chronic gastritis (Hp-gastritis) - antral predominant gastritis (APG) in 41.2%, pangastritis (PAN) in 52.9%, and corpus predominant (CPG) in 5.9%. Serum pepsinogen II levels were significantly higher, and the serum pepsinogen I : II ratio significantly lower, in the H. pylori positive group than in other groups. Within the Hp-gastritis group, there was a step-wise decrease in serum pepsinogen I levels with progression from APG through PAN to CPG pattern (a cut-off value of > or = 100 ng/ml would have identified APG with a positive predictive value of 77%, though with low sensitivity). Within the Hp-gastritis group, serum pepsinogen I and II levels were correlated with antral chronic inflammation score and serum pepsinogen II levels also with antral activity score. Serum pepsinogen I and the pepsinogen I : II ratio were lowest in severe gastric corpus atrophy.
CONCLUSION: In dyspeptic patients known to be infected with H. pylori, serum pepsinogen values provide an assessment of the overall topography of gastritis, the severity of antral inflammation and the presence of severe corpus atrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683924     DOI: 10.1046/j.1523-5378.2001.00031.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  18 in total

1.  Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium.

Authors:  Francesco Di Mario; Lucas Giovanni Cavallaro; Ali Mahamat Moussa; Pietro Caruana; Roberta Merli; Andrea Maini; Simone Bertolini; Nadia Dal Bó; Massimo Rugge; Giulia Martina Cavestro; Giovanni Aragona; Mario Plebani; Angelo Franzé; Giorgio Nervi
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

2.  The role of serum pepsinogen in the detection of gastric cancer.

Authors:  Nayoung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

3.  Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases.

Authors:  Pei-Fang Ning; Hui-Jie Liu; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

4.  Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index.

Authors:  Min Sun Kwak; Nayoung Kim; Hye Seung Lee; Hee Eun Lee; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2010-03-20       Impact factor: 3.199

Review 5.  Screening for and surveillance of gastric cancer.

Authors:  Debora Compare; Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

6.  Relation of atrophic gastritis with Helicobacter pylori-CagA(+) and interleukin-1 gene polymorphisms.

Authors:  Rafaela Sierra; Clas Une; Vanessa Ramirez; Warner Alpizar-Alpizar; Maria-I Gonzalez; Jose-A Ramirez; Antoine De Mascarel; Patricia Cuenca; Guillermo Perez-Perez; Francis Megraud
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

7.  Does Helicobacter pylori-induced inflammation of gastric mucosa determine the severity of symptoms in functional dyspepsia?

Authors:  Ebru Turkkan; Ihsan Uslan; Gursel Acarturk; Nevin Topak; Ahmet Kahraman; Fatma Husniye Dilek; Yusuf Akcan; Ozcan Karaman; Mehmet Colbay; Seref Yuksel
Journal:  J Gastroenterol       Date:  2009-01-22       Impact factor: 7.527

8.  Multifaceted Assessment of Chronic Gastritis: A Study of Correlations between Serological, Endoscopic, and Histological Diagnostics.

Authors:  Toshitatsu Takao; Takeshi Ishikawa; Takashi Ando; Madoka Takao; Tsuguhiro Matsumoto; Yutaka Isozaki; Mika Okita; Yasuyuki Nagao; Hirokazu Oyamada; Keiichi Yokoyama; Atsushi Tatebe; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Nobuaki Yagi; Satoshi Kokura; Yuji Naito; Toshikazu Yoshikawa
Journal:  Gastroenterol Res Pract       Date:  2011-07-10       Impact factor: 2.260

9.  Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis.

Authors:  Dariush Nasrollahzadeh; Karim Aghcheli; Masoud Sotoudeh; Ramin Shakeri; E Christina Persson; Farhad Islami; Farin Kamangar; Christian C Abnet; Paolo Boffetta; Lars Engstrand; Sanford M Dawsey; Reza Malekzadeh; Weimin Ye
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

10.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.